(MedPage Today) — The FDA has given the green light to an expanded access program (EAP) for the investigational pancreatic cancer drug daraxonrasib.
In a “safe to proceed” letter to Revolution Medicines, the FDA gave its approval to initiate…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
